GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (XCNQ:LOBE) » Definitions » Net-Net Working Capital

Lobe Sciences (XCNQ:LOBE) Net-Net Working Capital : C$-0.04 (As of Feb. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lobe Sciences Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Lobe Sciences's Net-Net Working Capital for the quarter that ended in Feb. 2024 was C$-0.04.

The industry rank for Lobe Sciences's Net-Net Working Capital or its related term are showing as below:

XCNQ:LOBE's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.275
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Lobe Sciences Net-Net Working Capital Historical Data

The historical data trend for Lobe Sciences's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences Net-Net Working Capital Chart

Lobe Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.01 0.18 -0.01 -0.03

Lobe Sciences Quarterly Data
Dec18 Mar19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 Aug23 Nov23 Feb24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 -0.03 -0.04 -0.04

Competitive Comparison of Lobe Sciences's Net-Net Working Capital

For the Biotechnology subindustry, Lobe Sciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lobe Sciences's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's Price-to-Net-Net-Working-Capital falls into.



Lobe Sciences Net-Net Working Capital Calculation

Lobe Sciences's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Aug. 2023 is calculated as

Net-Net Working Capital(A: Aug. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.14+0.75 * 0+0.5 * 0.017-2.46
-0-0)/79.1362
=-0.03

Lobe Sciences's Net-Net Working Capital (NNWC) per share for the quarter that ended in Feb. 2024 is calculated as

Net-Net Working Capital(Q: Feb. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.005+0.75 * 0.01+0.5 * 0.015-3.343
-0-0)/79.1362
=-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Lobe Sciences  (XCNQ:LOBE) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Lobe Sciences Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Lobe Sciences (XCNQ:LOBE) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5
Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.

Lobe Sciences (XCNQ:LOBE) Headlines

No Headlines